{"protocolSection": {"identificationModule": {"nctId": "NCT02273050", "orgStudyIdInfo": {"id": "D1680C00009"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control", "officialTitle": "A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control"}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-12"}, "primaryCompletionDateStruct": {"date": "2016-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-10-22", "studyFirstSubmitQcDate": "2014-10-22", "studyFirstPostDateStruct": {"date": "2014-10-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-08-01", "resultsFirstSubmitQcDate": "2017-08-01", "resultsFirstPostDateStruct": {"date": "2018-02-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-08-01", "lastUpdatePostDateStruct": {"date": "2018-02-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control", "detailedDescription": "Allocation: Randomized Endpoint Classification: Efficacy/Safety study Intervention Model: Parallel Assignment Masking: Double Blind Primary Purpose: Treatment"}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 Diabetes Mellitus, Dipeptidyl-Peptidase 4 Inhibitors, Saxagliptin, Metformin, Endocrine System Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1136, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin 5 mg + Metformin (500 mg with titration)", "type": "EXPERIMENTAL", "description": "Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.", "interventionNames": ["Drug: Saxagliptin 5 mg", "Drug: Metformin 500 mg with titration"]}, {"label": "Saxagliptin 5 mg + Placebo", "type": "ACTIVE_COMPARATOR", "description": "Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.", "interventionNames": ["Drug: Saxagliptin 5 mg", "Drug: Placebo 500 mg for metformin (with titration)"]}, {"label": "Metformin (500 mg with titration) + Placebo", "type": "ACTIVE_COMPARATOR", "description": "Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.", "interventionNames": ["Drug: Placebo 5 mg for Saxagliptin", "Drug: Metformin 500 mg with titration"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin 5 mg", "description": "Tablet, Oral, 5 mg, Once daily in the morning", "armGroupLabels": ["Saxagliptin 5 mg + Metformin (500 mg with titration)", "Saxagliptin 5 mg + Placebo"], "otherNames": ["Onglyza", "BMS-477118"]}, {"type": "DRUG", "name": "Placebo 5 mg for Saxagliptin", "description": "Tablet, Oral, 5 mg, Once daily in the morning", "armGroupLabels": ["Metformin (500 mg with titration) + Placebo"]}, {"type": "DRUG", "name": "Placebo 500 mg for metformin (with titration)", "description": "Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.", "armGroupLabels": ["Saxagliptin 5 mg + Placebo"]}, {"type": "DRUG", "name": "Metformin 500 mg with titration", "description": "Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.", "armGroupLabels": ["Metformin (500 mg with titration) + Placebo", "Saxagliptin 5 mg + Metformin (500 mg with titration)"], "otherNames": ["Glucophage"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.", "timeFrame": "Baseline to Week 24 (prior to rescue)"}], "secondaryOutcomes": [{"measure": "Glycemic Response Defined as HbA1c < 7.0% at Week 24", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \\< 7.0% at the end of 24 weeks of double-blinded treatment.", "timeFrame": "Week 24 (prior to rescue)"}, {"measure": "Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.", "timeFrame": "Baseline to Week 24 prior to rescue"}, {"measure": "Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.", "timeFrame": "Baseline to Week 24 prior to rescue"}, {"measure": "Glycemic Response Defined as HbA1c \u2264 6.5% at Week 24", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \u2264 6.5% at the end of 24 weeks of double-blinded treatment.", "timeFrame": "Week 24 (prior to rescue)"}, {"measure": "Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.", "timeFrame": "Baseline to Week 24 prior to rescue"}, {"measure": "Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.", "timeFrame": "Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects with type 2 diabetes mellitus; 2. HbA1c \u22658% but \u226412%; 3.Fasting C-peptide \u22651.0 ng/ml; 4. Subject will be drug na\u00efve; 5. Body mass index \u226440 kg/m2.\n\nExclusion Criteria:\n\n1. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent corticosteroid treatment ; 3. Calculated creatinine clearance \\<60 ml/min or serum creatinine \\>132.6 \u03bcmol/L (\\>1.5 mg/dL) for men, \\>123.8 \u03bcmol/L (\\>1.4 mg/dL) for women; 4. Creatine Kinase \u22653x ULN; 5.Abnormal TSH value at screening will be further evaluated by free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration of any antihyperglycaemic therapy for a total of 28 days or for more than three consecutive days or a total of seven non-consecutive days during the eight weeks prior to screening; 7. Current treatment with a strong CYP3A4/5 inhibitor; 8. Prior treatment with saxagliptin or any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease, renal disease, psychiatric disorders, Immunocompromised individuals, hemoglobinopathies, liver disease, Pancreatitis.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "100 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Changyu Pan, Professor", "affiliation": "The General Hospital of People's liberation Army", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Changchun", "country": "China", "geoPoint": {"lat": 43.88, "lon": 125.32278}}, {"facility": "Research Site", "city": "Chuangchun", "country": "China"}, {"facility": "Research Site", "city": "Fuzhou", "country": "China", "geoPoint": {"lat": 26.06139, "lon": 119.30611}}, {"facility": "Research Site", "city": "Guiyang", "country": "China", "geoPoint": {"lat": 26.58333, "lon": 106.71667}}, {"facility": "Research Site", "city": "Ha'er bin", "country": "China"}, {"facility": "Research Site", "city": "Hangzhou", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Hefei", "country": "China", "geoPoint": {"lat": 31.86389, "lon": 117.28083}}, {"facility": "Research Site", "city": "Jinan", "country": "China", "geoPoint": {"lat": 36.66833, "lon": 116.99722}}, {"facility": "Research Site", "city": "Nanchang", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}, {"facility": "Research Site", "city": "Nanjing", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Shijiazhuang", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "Research Site", "city": "Siping", "country": "China", "geoPoint": {"lat": 43.16143, "lon": 124.37785}}, {"facility": "Research Site", "city": "Tianjin", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Research Site", "city": "Wuxi", "country": "China", "geoPoint": {"lat": 31.56887, "lon": 120.28857}}, {"facility": "Research Site", "city": "Yueyang", "country": "China", "geoPoint": {"lat": 29.37455, "lon": 113.09481}}]}, "referencesModule": {"references": [{"pmid": "28926170", "type": "DERIVED", "citation": "Dou J, Ma J, Liu J, Wang C, Johnsson E, Yao H, Zhao J, Pan C. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab. 2018 Mar;20(3):590-598. doi: 10.1111/dom.13117. Epub 2017 Oct 26."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study duration was up to 27 weeks, consisting of an initial screening period lasting up to 2 weeks, a 1-week lead-in period, and a 24-week treatment period. The number of subjects who signed the ICF is 1136, the number of subjects randomized is 640.", "recruitmentDetails": "The study was conducted in 25 centers between 18 December 2014 and 03 August 2016.", "groups": [{"id": "FG000", "title": "METFORMIN + PLACEBO 5MG QD"}, {"id": "FG001", "title": "SAXAGLIPTIN 5MG QD + METFORMIN"}, {"id": "FG002", "title": "SAXAGLIPTIN 5MG QD + PLACEBO"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "210"}, {"groupId": "FG001", "numSubjects": "216"}, {"groupId": "FG002", "numSubjects": "214"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "186"}, {"groupId": "FG001", "numSubjects": "194"}, {"groupId": "FG002", "numSubjects": "185"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Dev. of study spec. withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "16"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "METFORMIN + PLACEBO 5MG QD"}, {"id": "BG001", "title": "SAXAGLIPTIN 5MG QD + METFORMIN"}, {"id": "BG002", "title": "SAXAGLIPTIN 5MG QD + PLACEBO"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "210"}, {"groupId": "BG001", "value": "216"}, {"groupId": "BG002", "value": "214"}, {"groupId": "BG003", "value": "640"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.1", "spread": "11.08", "lowerLimit": "20", "upperLimit": "75"}, {"groupId": "BG001", "value": "50.4", "spread": "10.78", "lowerLimit": "23", "upperLimit": "74"}, {"groupId": "BG002", "value": "49.5", "spread": "10.93", "lowerLimit": "24", "upperLimit": "74"}, {"groupId": "BG003", "value": "50.0", "spread": "10.92", "lowerLimit": "20", "upperLimit": "75"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "214"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "152"}, {"groupId": "BG003", "value": "426"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "210"}, {"groupId": "BG001", "value": "216"}, {"groupId": "BG002", "value": "214"}, {"groupId": "BG003", "value": "640"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, and had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% HbA1c", "timeFrame": "Baseline to Week 24 (prior to rescue)", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "212"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.007", "spread": "0.0706", "lowerLimit": "-3.146", "upperLimit": "-2.869"}, {"groupId": "OG001", "value": "-2.123", "spread": "0.0701", "lowerLimit": "-2.260", "upperLimit": "-1.985"}, {"groupId": "OG002", "value": "-2.794", "spread": "0.0715", "lowerLimit": "-2.935", "upperLimit": "-2.654"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.885", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.080", "ciUpperLimit": "-0.689", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0994"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.034", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.213", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.410", "ciUpperLimit": "-0.016", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1005"}]}, {"type": "SECONDARY", "title": "Glycemic Response Defined as HbA1c < 7.0% at Week 24", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \\< 7.0% at the end of 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, and had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Week 24 (prior to rescue)", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "212"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81.8"}, {"groupId": "OG001", "value": "44.3"}, {"groupId": "OG002", "value": "71.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "37.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "29.0", "ciUpperLimit": "46.0"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "10.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.6", "ciUpperLimit": "18.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, and had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline to Week 24 prior to rescue", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "213"}, {"groupId": "OG002", "value": "207"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.25", "spread": "0.112"}, {"groupId": "OG001", "value": "-1.86", "spread": "0.111"}, {"groupId": "OG002", "value": "-2.94", "spread": "0.113"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-1.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.70", "ciUpperLimit": "-1.08", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.158"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.046", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "0.00", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.159"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration, and participated in a meal tolerance test.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol*min/L", "timeFrame": "Baseline to Week 24 prior to rescue", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "117"}, {"groupId": "OG002", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1027.8", "spread": "36.22"}, {"groupId": "OG001", "value": "-611.9", "spread": "36.69"}, {"groupId": "OG002", "value": "-858.5", "spread": "37.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-416.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-517.3", "ciUpperLimit": "-314.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "51.54"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-169.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-271.7", "ciUpperLimit": "-66.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "52.05"}]}, {"type": "SECONDARY", "title": "Glycemic Response Defined as HbA1c \u2264 6.5% at Week 24", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \u2264 6.5% at the end of 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, and had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Week 24 (prior to rescue)", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "212"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.0"}, {"groupId": "OG001", "value": "32.1"}, {"groupId": "OG002", "value": "55.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "34.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "26.0", "ciUpperLimit": "43.9"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "11.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.3", "ciUpperLimit": "20.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration, and participated in a meal tolerance test.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline to Week 24 prior to rescue", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "116"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.09", "spread": "0.261"}, {"groupId": "OG001", "value": "-4.12", "spread": "0.262"}, {"groupId": "OG002", "value": "-5.95", "spread": "0.268"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-2.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.70", "ciUpperLimit": "-2.25", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.370"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-1.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.88", "ciUpperLimit": "-0.41", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.374"}]}, {"type": "SECONDARY", "title": "Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase", "description": "To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.", "populationDescription": "The full analysis set consisted of patients who were randomized, took at least 1 randomized study medication, and had both a baseline and at least 1 post-baseline efficacy assessment for the time point under consideration.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin + Metformin", "description": "Saxagliptin 5 mg + Metformin 500 mg"}, {"id": "OG001", "title": "Saxagliptin + Placebo", "description": "Saxagliptin 5 mg + Placebo"}, {"id": "OG002", "title": "Metformin + Placebo", "description": "Metformin 500 mg + Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "213"}, {"groupId": "OG002", "value": "207"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4"}, {"groupId": "OG001", "value": "10.3"}, {"groupId": "OG002", "value": "1.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "-8.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.3", "ciUpperLimit": "-4.5"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": ">0.999", "statisticalMethod": "Fisher Exact", "paramType": "Mean Difference (Net)", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "2.3"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Total number at risk is number of patients in safety analysis set (out of 640 randomized, 1 did not take study drug).", "eventGroups": [{"id": "EG000", "title": "METFORMIN + PLACEBO 5MG QD", "seriousNumAffected": 11, "seriousNumAtRisk": 210, "otherNumAffected": 30, "otherNumAtRisk": 210}, {"id": "EG001", "title": "SAXAGLIPTIN 5MG QD + METFORMIN", "seriousNumAffected": 4, "seriousNumAtRisk": 215, "otherNumAffected": 37, "otherNumAtRisk": 215}, {"id": "EG002", "title": "SAXAGLIPTIN 5MG QD + PLACEBO", "seriousNumAffected": 12, "seriousNumAtRisk": 214, "otherNumAffected": 21, "otherNumAtRisk": 214}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Diabetic retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Pancreatic mass", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Bile duct obstruction", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Hepatitis alcoholic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Chronic hepatitis B", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Adrenal adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Adrenal neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Diabetic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Diabetic nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Glomerulonephritis chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 214}]}, {"term": "Ureterolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Pulmonary mass", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}, {"term": "Phlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 13, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 17, "numAffected": 14, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 214}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 15, "numAffected": 15, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 11, "numAffected": 10, "numAtRisk": 214}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 210}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 215}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 214}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Eva Johnsson, MD, PhD", "organization": "AstraZeneca", "email": "Eva.Johnsson@astrazeneca.com", "phone": "46 31 7762484"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M22644", "name": "Acarbose", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}